Mucosal IL-4R Antagonist HIV Vaccination with SOSIP-gp140 Booster Can Induce High-quality Cytotoxic CD4/CD8 T Cells and Humoral Responses in Macaques

Overview

Journal Sci Rep

Specialty Science

Date 2020 Dec 17

PMID 33328567

Citations 6

Authors

Z Li

M Khanna

S L Grimley

P Ellenberg

C A Gonelli

Wen Shi Lee

T H Amarasena

A D Kelleher

D F J Purcell

S J Kent

C Ranasinghe

Affiliations

Soon will be listed here.

Abstract

Inducing humoral, cellular and mucosal immunity is likely to improve the effectiveness of HIV-1 vaccine strategies. Here, we tested a vaccine regimen in pigtail macaques using an intranasal (i.n.) recombinant Fowl Pox Virus (FPV)-gag pol env-IL-4R antagonist prime, intramuscular (i.m.) recombinant Modified Vaccinia Ankara Virus (MVA)-gag pol-IL-4R antagonist boost followed by an i.m SOSIP-gp140 boost. The viral vector-expressed IL-4R antagonist transiently inhibited IL-4/IL-13 signalling at the vaccination site. The SOSIP booster not only induced gp140-specific IgG, ADCC (antibody-dependent cellular cytotoxicity) and some neutralisation activity, but also bolstered the HIV-specific cellular and humoral responses. Specifically, superior sustained systemic and mucosal HIV Gag-specific poly-functional/cytotoxic CD4 and CD8 T cells were detected with the IL-4R antagonist adjuvanted strategy compared to the unadjuvanted control. In the systemic compartment elevated Granzyme K expression was linked to CD4 T cells, whilst Granzyme B/TIA-1 to CD8 T cells. In contrast, the cytotoxic marker expression by mucosal CD4 and CD8 T cells differed according to the mucosal compartment. This vector-based mucosal IL-4R antagonist/SOSIP booster strategy, which promotes cytotoxic mucosal CD4 T cells at the first line of defence, and cytotoxic CD4 and CD8 T cells plus functional antibodies in the blood, may prove valuable in combating mucosal infection with HIV-1 and warrants further investigation.

Citing Articles

TRPV4 is expressed by enteric glia and muscularis macrophages of the colon but does not play a prominent role in colonic motility.

Rajasekhar P, Carbone S, Johnston S, Nowell C, Wiklendt L, Crampin E bioRxiv. 2024; .

PMID: 38260314 PMC: 10802399. DOI: 10.1101/2024.01.09.574831.

Sublingual Immunization with Chimeric C1q/CD40 Ligand/HIV Virus-like Particles Induces Strong Mucosal Immune Responses against HIV.

Liu D, Zhang S, Poteet E, Marin-Muller C, Chen C, Yao Q Vaccines (Basel). 2021; 9(11).

PMID: 34835167 PMC: 8618657. DOI: 10.3390/vaccines9111236.

IL-13Rα2 Regulates the IL-13/IFN-γ Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination.

Li Z, Roy S, Ranasinghe C Vaccines (Basel). 2021; 9(5).

PMID: 34062727 PMC: 8147251. DOI: 10.3390/vaccines9050440.

STAT3 determines IL-4 signalling outcomes in naïve T cells.

Deimel L, Li Z, Roy S, Ranasinghe C Sci Rep. 2021; 11(1):10495.

PMID: 34006897 PMC: 8131749. DOI: 10.1038/s41598-021-89860-7.

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.

Chappell K, Mordant F, Li Z, Wijesundara D, Ellenberg P, Lackenby J Lancet Infect Dis. 2021; 21(10):1383-1394.

PMID: 33887208 PMC: 8055208. DOI: 10.1016/S1473-3099(21)00200-0.

References

McLean M, Madhavi V, Wines B, Hogarth P, Chung A, Kent S . Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial. J Immunol. 2017; 199(2):816-826. DOI: 10.4049/jimmunol.1602161. View

Center R, Wheatley A, Campbell S, Gaeguta A, Peut V, Alcantara S . Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine. 2009; 27(47):6605-12. DOI: 10.1016/j.vaccine.2009.08.016. View

Hemachandra A, Puls R, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S . An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin. 2010; 6(10):835-40. PMC: 3322532. DOI: 10.4161/hv.6.10.12635. View

Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N . A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol. 2015; 89(6):3380-95. PMC: 4337520. DOI: 10.1128/JVI.03473-14. View

Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C . Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A. 2008; 105(30):10501-6. PMC: 2483233. DOI: 10.1073/pnas.0804699105. View

Hanke T . STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev Vaccines. 2008; 7(3):303-9. DOI: 10.1586/14760584.7.3.303. View

Soghoian D, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T . HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med. 2012; 4(123):123ra25. PMC: 3918726. DOI: 10.1126/scitranslmed.3003165. View

Fouts T, Bagley K, Prado I, Bobb K, Schwartz J, Xu R . Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015; 112(9):E992-9. PMC: 4352796. DOI: 10.1073/pnas.1423669112. View

Adepoju P . Moving on from the failed HIV vaccine clinical trial. Lancet HIV. 2020; 7(3):e161. DOI: 10.1016/S2352-3018(20)30047-3. View

10.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

11.

Kent S, Dale C, Ranasinghe C, Stratov I, De Rose R, Chea S . Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine. 2005; 23(42):5009-21. DOI: 10.1016/j.vaccine.2005.05.032. View

12.

Belyakov I, Kuznetsov V, Kelsall B, Klinman D, Moniuszko M, Lemon M . Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood. 2005; 107(8):3258-64. PMC: 1895757. DOI: 10.1182/blood-2005-11-4374. View

13.

Kelleher A, Puls R, Bebbington M, Boyle D, Ffrench R, Kent S . A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS. 2006; 20(2):294-7. DOI: 10.1097/01.aids.0000199819.40079.e9. View

14.

Brumme Z, Brumme C, Heckerman D, Korber B, Daniels M, Carlson J . Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 2007; 3(7):e94. PMC: 1904471. DOI: 10.1371/journal.ppat.0030094. View

15.

Trivedi S, Jackson R, Ranasinghe C . Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity. Virology. 2014; 468-470:479-489. DOI: 10.1016/j.virol.2014.09.004. View

16.

Crotty S, Miller C, Lohman B, Neagu M, Compton L, Lu D . Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol. 2001; 75(16):7435-52. PMC: 114979. DOI: 10.1128/JVI.75.16.7435-7452.2001. View

17.

Veazey R, Lackner A . The mucosal immune system and HIV-1 infection. AIDS Rev. 2004; 5(4):245-52. View

18.

Abdel-Motal U, Gillis J, Manson K, Wyand M, Montefiori D, Stefano-Cole K . Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. Virology. 2005; 333(2):226-38. DOI: 10.1016/j.virol.2004.12.030. View

19.

Johnson S, Eller M, Teigler J, Maloveste S, Schultz B, Soghoian D . Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. J Virol. 2015; 89(15):7494-505. PMC: 4505667. DOI: 10.1128/JVI.00438-15. View

20.

Kalia V, Sarkar S, Gupta P, Montelaro R . Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41. J Virol. 2005; 79(4):2097-107. PMC: 546547. DOI: 10.1128/JVI.79.4.2097-2107.2005. View